Stabilization of Glomerular Filtration Rate in Advanced Chronic Kidney Disease: A Two-Year Follow-up of a Cohort of Chronic Kidney Disease Patients Stages 4 and 5
| Autor: | James Paparello, Cybele Ghossein, Shubhada N. Ahya, Vijayachitra Madhan, William Schlueter, Neenoo Khosla, Jie Huang, Daniel Batlle, Laura Nishi, Andres Serrano, Anupama Gangavathi, Paramesh Ramadugu |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Anemia medicine.medical_treatment Renal function urologic and male genital diseases Cohort Studies Renal Dialysis Internal medicine medicine Humans Intensive care medicine Dialysis Aged Aged 80 and over urogenital system business.industry Mortality rate Middle Aged medicine.disease female genital diseases and pregnancy complications Transplantation Treatment Outcome Nephrology Chronic Disease Cohort Kidney Failure Chronic Female Kidney Diseases business Glomerular Filtration Rate Cohort study Kidney disease |
| Zdroj: | Advances in Chronic Kidney Disease. 14:105-112 |
| ISSN: | 1548-5595 |
| Popis: | This study examines whether stabilization of the glomerular filtration rate (GFR) is possible in patients with advanced chronic kidney disease (CKD), managed in a CKD clinic. A cohort of 82 patients with stages 4 and 5 CKD was followed for a period of 2 years after initiation of erythropoietin for anemia to determine the GFR and the frequency of primary outcomes (dialysis, transplantation, or death). GFR, calculated by the abbreviated Modification of Diet in Renal Disease formula, was determined every 3 months. After 24 months, 35 subjects (43%) developed a primary outcome. Controlled for other risk factors, the risk of having a primary outcome increased 19.7% for every unit that the GFR decreased (95% confidence interval [CI], 11.9%-26.8%, P.001) and decreased 21.7% for every unit that the hemoglobin increased (95% CI, 0.5%-38.4%, P.001). Blacks had a 3.1 times higher risk (95% CI, 1.4-6.9, P = .006) of developing a primary outcome than other ethnicities. In subjects who did not develop primary outcomes (n = 47 or 57%), GFR remained unchanged (19.5 +/- 9.1 at the end of the study v 20.8 +/- 5.3 mL/min/1.73 m(2) at baseline, P = .16). The standardized mortality rate was 4.75 and 9.77 per 100 person-year for stages 4 and 5, respectively. We conclude that stabilization of GFR over a 2-year period can be achieved in many patients with advanced CKD treated with erythropoietin in a CKD clinic. Although the precise reason for the stabilization of GFR cannot be elucidated from this study, our data are "proof of concept" that CKD outcomes can be improved in a CKD clinic setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|